Gene-Editing hope: could a One-Time transplant fix sickle cell?

NCT ID NCT03653247

First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 21 times

Summary

This early-stage study tested a new treatment called BIVV003 for adults with severe sickle cell disease. The approach uses a person's own blood stem cells, which are gene-edited in a lab and then given back after chemotherapy. The main goals were to see if the treatment is safe and if the new cells start making healthy blood. Only 7 people took part, so results are very preliminary.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Healthcare of Atlanta

    Atlanta, Georgia, 30322, United States

  • Investigational Site Number 101

    Bethesda, Maryland, 20892, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • UCSF Benioff Children's Hospital

    Oakland, California, 94609, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

Conditions

Explore the condition pages connected to this study.